For example, NRAS is mutated in 13.7% of the AML patients from the Beat AML dataset, but is not modelled by Palma et al. The potential impact of NRAS on disease progression can be described with improved accuracy using the merged Palma-Ikonomi model (Fig. 3F). The gene discussed is NRAS; the disease is acute myeloid leukemia.